Beam Therapeutics announced the publication of Phase 1/2 BEACON trial data for risto-cel, a gene-edited cell therapy for sickle cell disease (SCD) with severe vaso-occlusive crises, in The New England Journal of Medicine. The data from 31 patients showed risto-cel's ability to increase fetal hemoglobin levels, reduce sickling, and eliminate severe pain crises with a favorable safety profile. The therapy requires only one stem cell collection cycle and shows rapid engraftment, improving patients' quality of life. Beam plans to submit a Biologics License Application to the FDA as early as the end of 2026, aiming to bring this potentially best-in-class treatment to market.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
